immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine

IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer

(PresseBox) ( Tübingen, )
immatics biotechnologies GmbH, a clinicalstage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, today announced it has signed a collaboration with Cancer Research UK for the further development of immatics' therapeutic cancer vaccine IMA950 in glioblastoma, the most aggressive form of brain cancer. Under the terms of the agreement, Cancer Research UK will sponsor and conduct a Phase I trial of IMA950 to be carried out at leading glioma research centres in the UK via its Drug Development Office. immatics will supply the drug IMA950 for the trial and also undertake immunomonitoring in the treated patients.

After the completion of the study, immatics will have an exclusive first right to take a license to the data for further development of IMA950. No financial details were disclosed.

Paul Higham, CEO of immatics said: "Cancer Research UK is a worldrenowned cancer research organisation and we are delighted that through this collaboration we will be able to efficiently move our third therapeutic cancer vaccine into the clinic, highlighting the wide applicability and productivity of our XPRESIDENT(TM) technology platform."

Dr Victoria John, head of clinical partnerships at Cancer Research UK's Drug Development Office, said: "We're very pleased to be taking on the next stage of this vaccine's development. This form of glioma is very difficult to treat successfully and we hope this trial will help to establish if the immatics vaccine might offer another viable treatment option for people with this type of cancer."

IMA950 is a therapeutic cancer vaccine generated through immatics' proprietary XPRESIDENT(TM) technology. It consists of 11 tumourassociated peptides (TUMAPs) which the immatics platform selects on the basis of their natural presentation by tumour tissue, immunogenicity and their relevance to tumour function. This unique approach to rationally designed therapeutic vaccines which are a combination of multiple, highly relevant tumour peptides is at the core of all immatics' clinical programmes.

For additional information on immatics please visit

About Cancer Research UK

- Cancer Research UK is the world's leading charity dedicated to beating cancer through research.
- The charity's groundbreaking work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. This work is funded entirely by the public.
- Cancer Research UK has been at the heart of the progress that has already seen survival rates double in the last thirty years.
- Cancer Research UK supports research into all aspects of cancer through the work of more than 4,800 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.

For further information about Cancer Research UK's work or to find out how to support the charity, please visit
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to